vs
Fifth Third Bancorp（FITB）与莫德纳（MRNA）财务数据对比。点击上方公司名可切换其他公司
Fifth Third Bancorp的季度营收约是莫德纳的1.5倍（$1.5B vs $1.0B），Fifth Third Bancorp净利率更高（47.7% vs -19.7%，领先67.4%），Fifth Third Bancorp同比增速更快（6.4% vs -45.4%），Fifth Third Bancorp自由现金流更多（$765.0M vs $-880.0M）
Fifth Third Bancorp是总部位于美国俄亥俄州辛辛那提的银行控股集团，为美国大型银行之一，位列《财富》美国500强第321位。旗下银行在全美12个州共运营1087家分行及2400台自动柜员机，服务覆盖多区域市场。
莫德纳是一家总部位于美国马萨诸塞州剑桥市的生物制药企业，深耕RNA治疗领域，核心业务聚焦mRNA疫苗研发。其疫苗通过信使RNA（mRNA）分子拷贝传递蛋白合成指令以触发人体免疫反应，公司名称由“修饰”“RNA”与“现代”三个词组合而来。
FITB vs MRNA — 直观对比
营收规模更大
FITB
是对方的1.5倍
$1.0B
营收增速更快
FITB
高出51.8%
-45.4%
净利率更高
FITB
高出67.4%
-19.7%
自由现金流更多
FITB
多$1.6B
$-880.0M
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.5B | $1.0B |
| 净利润 | $730.0M | $-200.0M |
| 毛利率 | — | 79.6% |
| 营业利润率 | 59.7% | -25.6% |
| 净利率 | 47.7% | -19.7% |
| 营收同比 | 6.4% | -45.4% |
| 净利润同比 | 17.7% | -1638.5% |
| 每股收益（稀释后） | $1.03 | $-0.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FITBMRNA
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.5B | $1.0B | ||
| Q2 25 | $1.5B | — | ||
| Q1 25 | $1.4B | — | ||
| Q4 24 | $1.4B | $966.0M | ||
| Q3 24 | — | $1.9B | ||
| Q4 23 | — | $2.8B | ||
| Q3 23 | — | $1.8B |
净利润FITBMRNA
| Q4 25 | $730.0M | — | ||
| Q3 25 | $649.0M | $-200.0M | ||
| Q2 25 | $628.0M | — | ||
| Q1 25 | $515.0M | — | ||
| Q4 24 | $620.0M | $-1.1B | ||
| Q3 24 | — | $13.0M | ||
| Q4 23 | — | $217.0M | ||
| Q3 23 | — | $-3.6B |
毛利率FITBMRNA
| Q4 25 | — | — | ||
| Q3 25 | — | 79.6% | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 23.5% | ||
| Q3 24 | — | 72.4% | ||
| Q4 23 | — | 67.0% | ||
| Q3 23 | — | -22.4% |
营业利润率FITBMRNA
| Q4 25 | 59.7% | — | ||
| Q3 25 | 55.1% | -25.6% | ||
| Q2 25 | 54.0% | — | ||
| Q1 25 | 45.4% | — | ||
| Q4 24 | 53.3% | -129.0% | ||
| Q3 24 | — | -3.8% | ||
| Q4 23 | — | 0.2% | ||
| Q3 23 | — | -109.9% |
净利率FITBMRNA
| Q4 25 | 47.7% | — | ||
| Q3 25 | 42.7% | -19.7% | ||
| Q2 25 | 42.0% | — | ||
| Q1 25 | 35.8% | — | ||
| Q4 24 | 43.1% | -115.9% | ||
| Q3 24 | — | 0.7% | ||
| Q4 23 | — | 7.7% | ||
| Q3 23 | — | -198.3% |
每股收益（稀释后）FITBMRNA
| Q4 25 | $1.03 | — | ||
| Q3 25 | $0.91 | $-0.51 | ||
| Q2 25 | $0.88 | — | ||
| Q1 25 | $0.71 | — | ||
| Q4 24 | $0.85 | $-2.91 | ||
| Q3 24 | — | $0.03 | ||
| Q4 23 | — | $0.63 | ||
| Q3 23 | — | $-9.53 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.1B |
| 总债务越低越好 | $13.6B | — |
| 股东权益账面价值 | $21.7B | $9.3B |
| 总资产 | $214.4B | $12.1B |
| 负债/权益比越低杠杆越低 | 0.63× | — |
8季度趋势，按日历期对齐
现金及短期投资FITBMRNA
| Q4 25 | — | — | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $1.9B | ||
| Q3 24 | — | $1.6B | ||
| Q4 23 | — | $2.9B | ||
| Q3 23 | — | $2.9B |
总债务FITBMRNA
| Q4 25 | $13.6B | — | ||
| Q3 25 | $13.7B | — | ||
| Q2 25 | $14.5B | — | ||
| Q1 25 | $14.5B | — | ||
| Q4 24 | $14.3B | — | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
股东权益FITBMRNA
| Q4 25 | $21.7B | — | ||
| Q3 25 | $21.1B | $9.3B | ||
| Q2 25 | $21.1B | — | ||
| Q1 25 | $20.4B | — | ||
| Q4 24 | $19.6B | $10.9B | ||
| Q3 24 | — | $11.9B | ||
| Q4 23 | — | $13.9B | ||
| Q3 23 | — | $13.5B |
总资产FITBMRNA
| Q4 25 | $214.4B | — | ||
| Q3 25 | $212.9B | $12.1B | ||
| Q2 25 | $210.0B | — | ||
| Q1 25 | $212.7B | — | ||
| Q4 24 | $212.9B | $14.1B | ||
| Q3 24 | — | $15.8B | ||
| Q4 23 | — | $18.4B | ||
| Q3 23 | — | $19.4B |
负债/权益比FITBMRNA
| Q4 25 | 0.63× | — | ||
| Q3 25 | 0.65× | — | ||
| Q2 25 | 0.69× | — | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 0.73× | — | ||
| Q3 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $929.0M | $-847.0M |
| 自由现金流经营现金流 - 资本支出 | $765.0M | $-880.0M |
| 自由现金流率自由现金流/营收 | 50.0% | -86.6% |
| 资本支出强度资本支出/营收 | 10.7% | 3.2% |
| 现金转化率经营现金流/净利润 | 1.27× | — |
| 过去12个月自由现金流最近4个季度 | $3.9B | $-1.9B |
8季度趋势，按日历期对齐
经营现金流FITBMRNA
| Q4 25 | $929.0M | — | ||
| Q3 25 | $1.0B | $-847.0M | ||
| Q2 25 | $1.3B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | $-101.0M | $825.0M | ||
| Q3 24 | — | $-1.6B | ||
| Q4 23 | — | $622.0M | ||
| Q3 23 | — | $-1.6B |
自由现金流FITBMRNA
| Q4 25 | $765.0M | — | ||
| Q3 25 | $886.0M | $-880.0M | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $-246.0M | $303.0M | ||
| Q3 24 | — | $-1.7B | ||
| Q4 23 | — | $402.0M | ||
| Q3 23 | — | $-1.7B |
自由现金流率FITBMRNA
| Q4 25 | 50.0% | — | ||
| Q3 25 | 58.3% | -86.6% | ||
| Q2 25 | 77.8% | — | ||
| Q1 25 | 77.7% | — | ||
| Q4 24 | -17.1% | 31.4% | ||
| Q3 24 | — | -92.2% | ||
| Q4 23 | — | 14.3% | ||
| Q3 23 | — | -95.0% |
资本支出强度FITBMRNA
| Q4 25 | 10.7% | — | ||
| Q3 25 | 10.5% | 3.2% | ||
| Q2 25 | 9.6% | — | ||
| Q1 25 | 8.1% | — | ||
| Q4 24 | 10.1% | 54.0% | ||
| Q3 24 | — | 8.1% | ||
| Q4 23 | — | 7.8% | ||
| Q3 23 | — | 7.6% |
现金转化率FITBMRNA
| Q4 25 | 1.27× | — | ||
| Q3 25 | 1.61× | — | ||
| Q2 25 | 2.08× | — | ||
| Q1 25 | 2.39× | — | ||
| Q4 24 | -0.16× | — | ||
| Q3 24 | — | -120.46× | ||
| Q4 23 | — | 2.87× | ||
| Q3 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FITB
暂无分部数据
MRNA
| COVID19 | $971.0M | 96% |
| Other Revenue | $20.0M | 2% |
| Grant | $14.0M | 1% |
| Collaboration Arrangement Including Arrangements With Affiliate | $7.0M | 1% |
| License And Royalty | $2.0M | 0% |
